Dynamic contrast-enhanced MRI in head-and-neck cancer: The impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 3, 2012, Pages

  Craciunescu, Oana I ^a   Yoo, David S ^a   Cleland, Esi ^b   Muradyan, Naira ^c   Carroll, Madeline D ^a   MacFall, James R ^a   Barboriak, Daniel P ^a   Brizel, David M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GECAD Ghana Ltd   (Ghana)

^c ICAD INC   (United States)

Author keywords

DCE MRI; Head and neck cancer; Pharmacokinetic analysis; ROI

Indexed keywords

BEVACIZUMAB; CLINICAL USE; COEFFICIENT OF VARIATION; CONCENTRATION-TIME; CONCURRENT CISPLATIN; CONTRAST-ENHANCED; DATA DISPERSION; DCE-MRI; DYNAMIC CONTRAST ENHANCED MRI; ERLOTINIB; EXTRACELLULAR VOLUMES; HEAD-AND-NECK CANCER; LYMPH NODE; MICROVASCULAR; PHARMACOKINETIC ANALYSIS; PHARMACOKINETIC PARAMETERS; REGION OF INTEREST; ROI; SAMPLING STRATEGIES;

DISEASES; PATIENT TREATMENT; PHARMACOKINETICS; PHYSIOLOGY; PLATINUM COMPOUNDS;

TUMORS;

BEVACIZUMAB; CISPLATIN; ERLOTINIB; TARCEVAL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADJUVANT THERAPY; ARTICLE; CHEMORADIOTHERAPY; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; HEAD AND NECK CANCER; HUMAN; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETERS; PHYSIOLOGY; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AREA UNDER CURVE; CHEMORADIOTHERAPY; CISPLATIN; CONTRAST MEDIA; GADOLINIUM DTPA; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE ENHANCEMENT; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MICROCIRCULATION; MOLECULAR TARGETED THERAPY; NORTH CAROLINA; QUINAZOLINES;

EID: 84856367846     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.05.059     Document Type: Article

References (20)

1. S. Sinha, and U. Sinha Recent advances in breast MRI and MRS NMR Biomed 22 2009 3 16
2. M.O. Leach, K.M. Brindle, and J.L. Evelhoch The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations Br J Cancer 92 2005 1599 1610
3. M.V. Knopp, H. von Tengg-Kobligk, and P.L. Choyke Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring Mol Cancer Ther 2 2003 419 426
4. P.S. Tofts, G. Brix, and D.L. Buckley Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols J Magn Reson Imaging 10 1999 223 232
5. J.L. Evelhoch Key factors in the acquisition of contrast kinetic data for oncology J Magn Reson Imaging 10 1999 254 259
6. C. Hayes, A.R. Padhani, and M.O. Leach Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging NMR Biomed 15 2002 154 163
7. M.D. Pickles, M. Lowry, and D.J. Manton Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy Breast Cancer Res Treat 91 2005 1 10
8. O. Craciunescu, D. Brizel, and E. Cleland Dynamic contrast enhanced-MRI in head and neck cancer patients: Variability of the precontrast longitudinal relaxation time (T10) Med Phys 37 2010 2683 2692
9. A.R. Padhani Dynamic contrast-enhanced MRI in clinical oncology: Current status and future directions J Magn Reson Imaging 16 2002 407 422
10. P.J. Hoskin, M.I. Saunders, and K. Goodchild Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer Br J Radiol 72 1999 1093 1098
11. P. Schmitt, M. Kotas, and A. Tobermann Quantitative tissue perfusion measurements in head and neck carcinoma patients before and during radiation therapy with a non-invasive MR imaging spin-labeling technique Radiother Oncol 67 2003 27 34
12. A. Quon, N.J. Fischbein, and I.R. McDougall Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma J Nucl Med 48 Suppl. 1 2007 58S 67S
13. Y. Cao, S. Mukherji, and C. Tsien TH-E-M100J-03: Early tumor response assessment of advanced head and neck cancer using DCE MRI Med Phys 34 2007 2649
14. J. Asaumi, Y. Yanagi, and H. Konouchi Application of dynamic contrast-enhanced MRI to differentiate malignant lymphoma from squamous cell carcinoma in the head and neck Oral Oncol 40 2004 579 584
15. Y. Cao, A. Popovtzer, and D. Li Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: A prospective study Int J Radiat Oncol Biol Phys 72 2008 1287 1290
16. J.F. Jansen, H. Schoder, and N.Y. Lee Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases Int J Radiat Oncol Biol Phys 77 2010 1403 1410
17. K. Newbold, I. Castellano, and E. Charles-Edwards An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer Int J Radiat Oncol Biol Phys 74 2009 29 37
18. J.P. Machiels, S. Henry, and S. Zanetta Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01 J Clin Oncol 28 2010 21 28
19. S. Bisdas, O. Seitz, and M. Middendorp An exploratory pilot study into the association between microcirculatory parameters derived by MRI-based pharmacokinetic analysis and glucose utilization estimated by PET-CT imaging in head and neck cancer Eur Radiol 20 2010 2358 2366
20. G.J. Parker, J. Suckling, and S.F. Tanner Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics J Magn Reson Imaging 7 1997 564 574